Innovent Reports Positive Results for PD-1 Candidate; Files China NDA

21:02 EDT 17 May 2018 | ChinaBio Today

Innovent Biologics of Suzhou reported strong preliminary results from a China Phase II trial of its PD-1 candidate, sintilimab (IBI308). In 96 patients with relapsed/refractory classical Hodgkin Lymphoma, sintilimab produced an overall response rate of 79% and a disease control rate of 98%, meeting the endpoints of the study. Innovent said it submitted an NDA to the CFDA for sintilimab on April 19, 2018, which will be reviewed following speeded-up Priority Review rules. More details....

Share this with colleagues:

Original Article: Innovent Reports Positive Results for PD-1 Candidate; Files China NDA


More From BioPortfolio on "Innovent Reports Positive Results for PD-1 Candidate; Files China NDA"

Quick Search


Relevant Topics

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Hodgkin lymphoma
Hodgkin Lymphoma is a  disorder caused by malignant proliferation of lymphocytes, which contain characteristic mirror-image nuclei (Reed-Sternburg cells). The resulting lymphadenopathy can be limited to a single lymph node region (Stage 1) or spread...